IASIS PHARMA has launched a new pharmaceutical product under the brand name Lartokaz.  It is an Irbesartan/hydrochlorothiazide combination preparation in two strengths: (150+12,5)mg/tab and (300+12,5)mg/tab respectively. Irbesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension and in a combination formulation with hydrochlorothiazide(diuretic), is able to achieve an additive antihypertensive effect.